Prices delayed by at least 15 minutes | Print


MAUNA KEA TECH (ALMKT)

MAUNA KEA TECHNOLOGIES S.A.
Sell: €0.397|Buy: €0.4|Change: 0.00 (-0.50%)

Open 

€0.399


Previous close 

€0.4


Trade high 

€0.4


Volume 

31,791


Year high 

€0.77


Year low 

€0.34


Dividend yield 

-


Market capitalisation 

€24.49 mn


P/E ratio 

-


ISIN 

FR0010609263


This share can be held in a Dealing accountISALifetime ISAJISASIPP

Share price

Performance 06/05/2024

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
MAUNA KEA TECH- 0.50
More...

Company profile

Mauna Kea Technologies SA is a medical device corporation. It is engaged in designing, developing, and marketing an imaging platform used to view tissues at a cellular level, in real-time, during standard procedures. The firm operates in the business segment of Endomicroscopy. The group's technological platform is Cellvizio which helps physicians to detect early-stage pathologies more accurately and make therapeutic decisions. It generates revenue from the sales of Cellvizioproducts and accessories used for medical diagnostics, research, and related services. The company sells its products in France and internationally, of which the majority of the revenue is derived from America.

Sector 

Healthcare


AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.